Allogene Therapeutics, Inc.
ALLO
$1.45
$0.053.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 0.58% | -11.20% | |||
| Gross Profit | -0.58% | 11.20% | |||
| SG&A Expenses | -4.99% | 1.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.91% | -8.12% | |||
| Operating Income | 0.91% | 8.12% | |||
| Income Before Tax | 10.25% | 0.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.58% | 0.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.58% | 0.10% | |||
| EBIT | 0.91% | 8.12% | |||
| EBITDA | 1.01% | 7.90% | |||
| EPS Basic | 10.19% | 9.25% | |||
| Normalized Basic EPS | -2.89% | 17.74% | |||
| EPS Diluted | 10.19% | 9.25% | |||
| Normalized Diluted EPS | -2.89% | 17.74% | |||
| Average Basic Shares Outstanding | 0.66% | 10.08% | |||
| Average Diluted Shares Outstanding | 0.66% | 10.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||